China: Food and Drugs Law

The US Department of Health and Human Services has launched Operation TrialBlazer to address China's growing dominance in clinical research and restore American leadership in biomedical innovation. As Chinese clinical trials now surpass US trials in both speed and volume, this comprehensive initiative aims to modernize regulatory processes, reduce administrative burdens, and reverse the trend of research investment flowing overseas.

上述孙文和蒋文均聚焦于《专利审查指南》第五部分第九章第3.5节“新药相关技术方案应当以国务院药品监督管理部门批准的新药的结构、组成及其含量，批准的生产工艺和适应症为准。指定权利要求未包括获得上市许可的新药相关技术方案的，不予期限补偿”的规定，进行分析和论证，然而

China's National Medical Products Administration has officially implemented new drug trial data protection measures, establishing a comprehensive framework that grants varying protection periods based on innovation levels.

China has emerged as a global pharmaceutical innovation powerhouse, leveraging its scientific expertise, AI capabilities, and streamlined regulatory environment to accelerate drug development.

Chinese regulators intensified anti-corruption enforcement in the life sciences sector during 2026, with particular emphasis on medical insurance fraud, investigator-initiated studies, and patient programs.

山東省高級人民法院（高裁）はこのほど、2025年の知的財産分野における懲罰的賠償の典型事例を公表した...

On August 28, 2024, the National Medical Products Administration (NMPA) released the Medical Device Administration Law (Draft for Comment)...

The fourth amendment to the Patent Law of the People's Republic of China (hereinafter, the "Patent Law") came into effect on June 1, 2021. In July of the same year, the Measures for the Implementation...

Chinese authorities have launched a special "Hundred-Day Campaign" to target misconduct relating to China's state-run medical insurance program and issued a new Ethical Code for Healthcare Professionals...